Research

We study the transplant of hematopoietic progenitors and its complications and develop new academic CAR-T cells enriched in T-memory stem cells to treat T and B Hodgkin lymphomas.

The main goals of our research are: 

• Identify new prognostic parameters for risk and therapeutic stratifications.
• Molecularly characterize acute myeloid leukemia and determine the prognostic value of known genes and other genes of uncertain significance.
• Evaluate targeted therapy in cell lines and animal models (together with Dr. Mangues’ group).
• Reduce toxicity and increase the availability of allogeneic transplants.
• Preclinical (mouse) and clinical studies on immunotherapy for lymphoproliferative diseases. Development of non-commercial CAR-T cell therapies.

It is paramount that we improve the prognosis of hematological patients by using new more precise therapies, and less toxic. Therefore, through our research, we aim to: 

• Improve the genotypic and immunophenotypic characterization of AML and CLL, to identify new prognostic factors and administer targeted therapy.
• Improve the safety and effectiveness of hematopoietic transplantation and expand the number of patients who can benefit from it.
• Develop new CAR-T products that enhance the currently commercially available ones.